HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice.

Abstract
Mesopram, a specific inhibitor of type-4 phosphodiesterase, decreases the synthesis of tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma). In the present study, we investigated the effect of mesopram in dextran sulfate sodium (DSS)-induced murine colitis. In the preventive model, colitis was induced by DSS simultaneously with the application of mesopram in BALB/c mice. In the therapeutic model, colitis was induced in BALB/c mice by DSS over 7 days. At day 8, DSS was discontinued, and treatment was started. Mesopram was applied intraperitoneally or orally. The clinical score was calculated daily during the course of each study. Post mortem, colon length, histologic score, and expression of TNF-alpha and IFN-gamma in colons were determined. In the preventive model, mesopram significantly reduced the maximal clinical score, decreased colon shortening, and the histologic score. A dose finding study, using the preventive model, showed that most clinical and post mortem benefit was achieved with 50 mg/kg mesopram compared with 2 and 10 mg/kg. In the therapeutic model, i.p. mesopram treatment led to a significant reduction of clinical score. Both, i.p. and p.o. mesopram significantly reversed DSS-induced colon shortening and reduced the ex vivo colonic production of IFN-gamma. We conclude that the specific type-4 phosphodiesterase inhibitor mesopram ameliorates murine colitis both in a preventive and a therapeutic setting.
AuthorsFlorian Loher, Kathrin Schmall, Philipp Freytag, Nikola Landauer, Roland Hallwachs, Christian Bauer, Britta Siegmund, Florian Rieder, Hans-Anton Lehr, Marc Dauer, Joachim Friedrich Kapp, Stefan Endres, Andreas Eigler
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 305 Issue 2 Pg. 549-56 (May 2003) ISSN: 0022-3565 [Print] United States
PMID12606674 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Aminosalicylic Acids
  • Cytokines
  • Oxazoles
  • Phosphodiesterase Inhibitors
  • Tumor Necrosis Factor-alpha
  • mesopram
  • Interferon-gamma
  • Dextran Sulfate
  • 3',5'-Cyclic-AMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 4
  • olsalazine
Topics
  • 3',5'-Cyclic-AMP Phosphodiesterases (antagonists & inhibitors)
  • Aminosalicylic Acids (therapeutic use)
  • Animals
  • Colitis (chemically induced, drug therapy, pathology)
  • Colon (pathology)
  • Cyclic Nucleotide Phosphodiesterases, Type 4
  • Cytokines (biosynthesis)
  • Dextran Sulfate
  • Dose-Response Relationship, Drug
  • Female
  • Interferon-gamma (biosynthesis)
  • Mice
  • Mice, Inbred BALB C
  • Oxazoles (therapeutic use)
  • Phosphodiesterase Inhibitors (therapeutic use)
  • Tumor Necrosis Factor-alpha (biosynthesis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: